A Randomized, Open-Label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of BTH1677 (1,3–1,6 Beta Glucan; Imprime PGG) In Combination with Cetuximab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.

by | Sep 28, 2018 | Cancer, Immunotherapy

Invest New Drugs 2017 – Thomas, M., Sadjadian, P., Kollmeier, J., Lowe, J., Mattson, P., Trout, J., . . . Schneller, F., III. (2017, March 1). A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta...